2024-10-21 11:29:00
Sanofi announced that it has entered into exclusive negotiations with the CD&R investment fund to sell it 50% of its subsidiary Opella. The sale is accompanied by various commitments, which expose the seller and buyer to heavy penalties.
The outcome ahead of the “Doliprane” saga. Sanofi’s board of directors announced Monday that it has entered into exclusive negotiations with the investment fund CD&R to sell it 50% of its subsidiary Opella. The CD&R offer is “solid and fully funded”indicates the pharmaceutical giant in a press release, specifying that the evaluation of the subsidiary «general public» is based on an enterprise value of approximately 16 billion euros, which corresponds to 14 times the Ebitda estimated for 2024. The completion of this operation, which should allow the pharmaceutical giant to focus on innovative drugs and vaccines, is expected by second quarter of 2024. 2025 at the earliest.
Sanofi will stay “a major shareholder of Opella”for the moment around 48%, which will allow him to retain part of the company’s future value creation. He will not be alone: the public investment bank Bpifrance will participate in…
#Production #volume #job #retention.. #State #lifts #veil #conditions #set #sale #Opella #Doliprane